Literature DB >> 27699575

Analysis of thrombosis and bleeding complications in patients with polycythemia vera: a Turkish retrospective study.

A M Yesilova1, S Yavuzer2, H Yavuzer3, M Cengiz3, I D Toprak1, E Hanedar4, M C Ar5, Z Baslar5.   

Abstract

The aims of this study are to determine the incidence and risk factors of thrombosis and bleeding in polycythemia vera (PV) patients and to research the effects of these risk factors on survival. The medical records of 155 PV patients were analyzed retrospectively. Patients were divided into groups according to whether or not thrombosis had developed in follow-up, and according to whether or not bleeding had occurred during follow-up. The mean age at diagnosis was 53 years, and the mean follow-up period was 66 months. The percentage of cases in which thrombosis events had occurred before diagnosis and during follow-up were 26 and 28 %, respectively. Comparisons of disease duration and average thrombosis risk score between groups with or without thrombosis drew statistically significant results. A patient's history of thrombosis and thrombocytosis at first visit was found to have a significant effect on thrombosis recurrence. The major bleeding rate was 8 %. Post-PV myelofibrosis was an independent risk factor for bleeding. The major cause of death among the patients in this study was primary thrombosis. The most important causes of mortality among PV patients are thrombosis, and the most prominent risk factors for thrombosis development are disease duration and high thrombosis risk scores. Thrombocytosis in patients with a history of thrombosis may cause thrombosis recurrence during the follow-up period.

Entities:  

Keywords:  Bleeding; Polycythemia vera; Thrombosis

Mesh:

Year:  2016        PMID: 27699575     DOI: 10.1007/s12185-016-2105-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  33 in total

1.  Complications and causes of death in polycythaemia vera.

Authors:  E CHIEVITZ; T THIEDE
Journal:  Acta Med Scand       Date:  1962-11

2.  Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors.

Authors:  M H Denninger; Y Chaït; N Casadevall; S Hillaire; M C Guillin; A Bezeaud; S Erlinger; J Briere; D Valla
Journal:  Hepatology       Date:  2000-03       Impact factor: 17.425

3.  Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.

Authors:  Guido Finazzi; Alessandro Rambaldi; Vittoria Guerini; Alessandra Carobbo; Tiziano Barbui
Journal:  Haematologica       Date:  2007-01       Impact factor: 9.941

Review 4.  Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

Authors:  A Tefferi; J W Vardiman
Journal:  Leukemia       Date:  2007-09-20       Impact factor: 11.528

5.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi
Journal:  N Engl J Med       Date:  2015-04-23       Impact factor: 91.245

6.  Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.

Authors:  Yoojoo Lim; Jeong-Ok Lee; Se Hyun Kim; Jin Won Kim; Yu Jung Kim; Keun-Wook Lee; Jong Seok Lee; Soo-Mee Bang
Journal:  Thromb Res       Date:  2015-02-26       Impact factor: 3.944

7.  The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.

Authors:  Michael Deininger; Jerald Radich; Timothy C Burn; Reid Huber; Dilan Paranagama; Srdan Verstovsek
Journal:  Blood       Date:  2015-07-30       Impact factor: 22.113

8.  The genetic basis of myeloproliferative disorders.

Authors:  Radek Skoda
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2007

9.  Efficacy and safety of low-dose aspirin in polycythemia vera.

Authors:  Raffaele Landolfi; Roberto Marchioli; Jack Kutti; Heinz Gisslinger; Gianni Tognoni; Carlo Patrono; Tiziano Barbui
Journal:  N Engl J Med       Date:  2004-01-08       Impact factor: 91.245

10.  Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort.

Authors:  Elizabeth M Kander; Sania Raza; Zheng Zhou; Juehua Gao; Anaadriana Zakarija; Brandon J McMahon; Brady L Stein
Journal:  Int J Hematol       Date:  2015-10-06       Impact factor: 2.490

View more
  2 in total

1.  Thrombohemorrhagic events, disease progression, and survival in polycythemia vera and essential thrombocythemia: a retrospective survey in Miyazaki prefecture, Japan.

Authors:  Ayako Kamiunten; Kotaro Shide; Takuro Kameda; Masaaki Sekine; Yoko Kubuki; Masafumi Ito; Takanori Toyama; Noriaki Kawano; Kousuke Marutsuka; Kouichi Maeda; Masanori Takeuchi; Hiroshi Kawano; Seiichi Sato; Junzo Ishizaki; Keiichi Akizuki; Yuki Tahira; Haruko Shimoda; Tomonori Hidaka; Kiyoshi Yamashita; Hitoshi Matsuoka; Kazuya Shimoda
Journal:  Int J Hematol       Date:  2018-02-27       Impact factor: 2.490

2.  Therapeutic Plateletpheresis in Patients With Thrombocytosis: Gender, Hemoglobin Before Apheresis Significantly Affect Collection Efficiency.

Authors:  Hongqiang Jiang; Yanxia Jin; Yufeng Shang; Guolin Yuan; Dandan Liu; Jianfang Li; Cong Wang; Lu Ding; Xiqin Tong; Shishang Guo; Fayun Gong; Fuling Zhou
Journal:  Front Med (Lausanne)       Date:  2021-12-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.